Abstract: A system and method for clustered failover of storage appliances is provided. In the event of a failover of one storage appliance to a surviving storage appliance, the surviving storage appliance assumes the identity of the failed storage appliance. This assumption of the identifier is accomplished by initializing a Fibre Channel Host Bus Adapter on the surviving storage appliance with the NodeName and PortNames of the failed storage appliance.

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.

Abstract: The present invention provides methods for isolating and characterizing the glycosylation sites of a glycoprotein, such as a glycosylated antibody. In particular, the methods employ affinity capture, liquid chromatography, and mass spectrometry to determine, for example, the location of the glycopeptide, the heterogeneity of the glycan attached to the glycopeptide, the mass of the glycopeptide, and/or the peptide sequence.

Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-4 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-4, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-2, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-5 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-5, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.

Abstract: A technique enhances a write data path within a storage operating system executing on a storage system. As used herein, the write data path defines program logic used by a file system of the storage operating system to process write requests directed to data served by the file system. The technique enhances the write data path of the storage system by providing a “zero copy” write data path embodied as a function of the storage operating system that eliminates a copy operation for a write request received at the storage system. The eliminated operation is a data copy operation from a list of input buffers to buffers used by the file system.

Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Abstract: A technique enables efficient access to logical unit numbers (luns) or virtual disks (vdisks) stored on a storage system, such as a multi-protocol storage appliance. The technique allows a grouping of initiators by a “human friendly” logical name that is mapped to a lun or vdisk on the storage appliance. The initiators are clients operating in, e.g., a storage area network (SAN) environment that initiate requests for the vdisk using block-based access protocols, such as the Small Computer Systems Interface (SCSI) protocol encapsulated over TCP/IP (iSCSI) or over fibre channel (FCP). The technique enables access to the vdisk by all initiators that are members of the initiator group (igroup). An igroup is a logical named entity that is assigned to one or more addresses associated with one or more initiators. These addresses may comprise fibre channel (FC) world wide name (WWN) or iSCSI name identifiers (IDs).

Abstract: A system and method for clustered failover of storage appliances is provided. In the event of a failover of one storage appliance to a surviving storage appliance, the surviving storage appliance assumes the identity of the failed storage appliance. This assumption of the identifier is accomplished by initializing a Fibre Channel Host Bus Adapter on the surviving storage appliance with the NodeName and PortNames of the failed storage appliance.

Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Abstract: A system and method enabling transparent access to blocks, such as virtual disks, stored on a storage system using a file-based protocol. The system and method traps in-coming file-based protocol open commands to check for a predetermined modification to the file name. If the system and method detects the predetermined modification, then the virtual disk associated with the file name is exported to the client issuing the open command and the client receives a response from the storage system. The client, in response to receiving the response to the open command, creates a new device instantiation for reading and writing raw data to the virtual disk.

Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Abstract: A system and method for optimizing lun masking of a storage appliance is provided. Upon login, an initiator data structure containing a lun map is created and associated with each initiator connected to the storage system. When an initiator sends a message directed to a lun associated with the storage system, the storage system maps the lun sent by the initiator to a physical lun associated with the storage system using the lun map. If the lun map contains an appropriate entry, then the lun has been successfully exported and/or masked to the given initiator.

Abstract: A system and method enabling transparent access to blocks, such as virtual disks, stored on a storage system using a file-based protocol. The system and method traps incoming file-based protocol open commands to check for a predetermined modification to the file name. If the system and method detects the predetermined modification, then the virtual disk associated with the file name is exported to the client issuing the open command and the client receives a response from the storage system. The client, in response to receiving the response to the open command, creates a new device instantiation for reading and writing raw data to the virtual disk.

Abstract: A storage virtualization selection technique “automates” a virtualization selection process to create virtual disk (vdisk) storage objects over a volume of a file system implemented by a storage operating system of a multi-protocol storage appliance. The file system provides a virtualization system that aggregates physical storage of a set of disks or portions (e.g., extents) of disks into a pool of blocks that can be dynamically allocated to form a vdisk. The file system also provides reliability guarantees for the vdisks in accordance with its underlying architecture. That is, the file system organizes its storage within volumes created among the managed disks. The vdisk is thereafter created as a storage object within a volume and, thus, inherits the underlying reliability configuration associated with that volume.

Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.

Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.